Holen Sie sich die Stockscreener-App
13.17
0.61%
0.08
Vorhandelsmarkt:
13.85
0.68
+5.16%
Schlusskurs vom Vortag:
$13.09
Offen:
$13.21
24-Stunden-Volumen:
236.39K
Relative Volume:
0.87
Marktkapitalisierung:
$685.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.43M
KGV:
-16.67
EPS:
-0.79
Netto-Cashflow:
$-39.97M
1W Leistung:
-2.95%
1M Leistung:
-2.52%
6M Leistung:
+46.82%
1J Leistung:
+104.50%
1-Tages-Spanne:
$12.85
$13.54
1-Wochen-Bereich:
$12.67
$13.79
52-Wochen-Spanne:
$6.189
$20.50
Gh Research Plc Stock (GHRS) Company Profile
Vergleichen Sie GHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
13.17 | 811.96M | 0 | -41.43M | -39.97M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2025-03-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-02-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-16 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
GH Research Showcases Promising Depression Treatment at ECNP 2025 - TipRanks
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress - The Manila Times
GH Research PLC Announces Acceptance of Presentation and Posters on GH001 for Treatment-Resistant Depression at ECNP Congress - Quiver Quantitative
No treatment-related SAEs: GH Research 6‑Month GH001 safety & psychoactive data for TRD at ECNP 2025 - Stock Titan
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress - GlobeNewswire Inc.
Can a trend reversal in GH Research PLC lead to recoveryMarket Trend Review & Free Technical Confirmation Trade Alerts - newser.com
Using fundamentals and technicals on GH Research PLCJuly 2025 Action & Weekly High Potential Alerts - newser.com
GH Research PLC stock momentum explainedJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
GH Research's (GHRS) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
How GH Research PLC stock responds to policy changesPrice Action & Daily Stock Momentum Reports - newser.com
Market reaction to GH Research PLC’s recent newsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Can volume confirm reversal in GH Research PLCQuarterly Risk Review & High Win Rate Trade Alerts - newser.com
Will GH Research PLC stock outperform international peers2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Has GH Research PLC found a price floorJuly 2025 Summary & Real-Time Volume Analysis Alerts - newser.com
Does GH Research PLC qualify in momentum factor screeningMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Is GH Research PLC stock cheap at current valuationBuy Signal & Verified Swing Trading Watchlists - newser.com
Will GH Research PLC stock benefit from automationWall Street Watch & Low Drawdown Investment Ideas - newser.com
Why millennials buy GH Research PLC (1KA) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Is GH Research PLC stock a buy in volatile markets2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
What drives GH Research PLC 1KA stock priceMonthly Performance Summary & Free Smart Trading Classes - earlytimes.in
H.C. Wainwright maintains buy on GH Research stock, $40 target - MSN
Finanzdaten der Gh Research Plc-Aktie (GHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
4.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):